NCT03940183View on ClinicalTrials.gov

Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

December 3, 2020

Study Completion Date

December 28, 2020

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Trelagliptin Succinate

the experimental group will use trelagliptin succinate 100 mg for 24weeks

DRUG

Placebo Oral Tablet

the placebo Comparator groups use placebo oral tablet for 24weeks

Trial Locations (1)

Unknown

Beijing Hospital, Beijing

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT03940183 - Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes | Biotech Hunter | Biotech Hunter